Heart attack drug trial halted: could quick cholesterol drop save hearts?

NCT ID NCT05613426

Terminated Disease control Sponsor: Henan Institute of Cardiovascular Epidemiology Source: ClinicalTrials.gov ↗

First seen May 23, 2026 · Last updated Jun 17, 2026 · Updated 4 times

Summary

This study looked at whether giving a powerful cholesterol-lowering drug (evolocumab) very early after a major heart attack could help the heart pump better and prevent long-term damage. About 119 adults who were having a heart attack and scheduled for a procedure to open blocked arteries took part. The study was stopped early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ST-ELEVATION MYOCARDIAL INFARCTION (STEMI) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Fuwai Central China Cardiovascular Hospital

Zhengzhou, Henan, China
Hopeshine Minsheng Hospital of Xinzheng

Xinzheng, Henan, China
Kaifeng Central Hospital

Kaifeng, Henan, China
The People's Hospital of Changyuan

Xinxiang, Henan, China
The People's Hospital of Gongyi

Gongyi, Henan, China
The People's Hospital of Xuchang

Xuchang, Henan, China

Conditions

The condition(s) this trial relates to.

ST-elevation myocardial infarction Ventricular Remodeling

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ST-ELEVATION MYOCARDIAL INFARCTION (STEMI)